Data as of Dec 19
| +0.21 / --|
Ocata Therapeutics, Inc. is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA.
|Paul K. Wotton||President, Chief Executive Officer & Director|
|Edward H. Myles||Chief Operating & Financial Officer|
|Robert P. Lanza||Chief Scientific Officer|
|Eddy Anglade||Executive Vice President-Clinical Development|
|Shi-Jiang Lu||Senior Director-Research|